Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma (NCT04134325)

🧪 Interventions in This Study

• Nivolumab (BIOLOGICAL)
• Pembrolizumab (BIOLOGICAL)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. for Arm 1: Relapse After Prior CD 30 CAR-T Therapy
2. Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
3. Age ≥18 years at the time of consent.
4. Subject is planned to start on standard of care anti-PD-1 therapy per community standards of medical care by their treating oncologist.
5. Subject has a diagnosis of relapsed/refractory classical Hodgkin lymphoma after at least three lines of prior therapy with clinical progression after either ATLCAR.CD30 and/or ATLCAR.CD30.CCR4. The CAR-T cell product may be either the UNC, Baylor or Tessa product.
6. Subjects with prior allogeneic stem cell transplant will be eligible but will be counseled during consent regarding possible increased risk of graft versus host disease with anti-PD-1 therapy after allogeneic stem cell transplant.
7. Subjects must have previously been treated with anti-PD-1 therapy (any anti-PD-1 therapy either standard of care or investigational) prior to receiving autologous CAR-T-cell therapy.
8. Subject is willing to provide blood samples that are clinically necessary during anti-PD-1 therapy administered per community standards of medical care. Inclusion Criteria for Arm 2: Relapse with no Prior CD 30 CAR-T Therapy
9. Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
10. Age ≥18 years at the time of consent.
11. Subject is planned to start on standard of care anti-PD-1 therapy per community standards of medical care by their treating oncologist.
12. Subject has a diagnosis of classical Hodgkin lymphoma.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Lineberger Comprehensive Cancer Center at University of North Carolina — Chapel Hill, North Carolina

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Relapsed Hodgkin Lymphoma

• A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL — Indianapolis, Indiana

Explore by condition: All Relapsed Hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.